Antitumor Activity of a Combination of rAd2p53 Adenoviral Gene Therapy and Radiotherapy in Esophageal Carcinoma

Cell Biochemistry and Biophysics

Volumn 59, Issue 3, 2011, Pages 147-152

  Lu, Ping ^a,b   Yang, Xiaoyu ^c   Huang, Yanmei ^c   Lu, Zhihong ^a   Miao, Zhanhui ^a   Liang, Qiudong ^a   Zhu, Yanli ^a   Fan, Qingxia ^b  

^a First Affiliated Hospital of Xinxiang Medical College   (China)

^b THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^c XINXIANG MEDICAL UNIVERSITY   (China)

Author keywords

Esophageal carcinoma; rAd2p53 adenoviral gene; Radiotherapy

Indexed keywords

RECOMBINANT PROTEIN;

ADENOVIRUS; ARTICLE; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ESOPHAGUS TUMOR; FEMALE; GENE THERAPY; GENETICS; HUMAN; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; RANDOMIZED CONTROLLED TRIAL; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE;

ADENOVIRIDAE; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; ESOPHAGEAL NEOPLASMS; FEMALE; GENE THERAPY; GENES, P53; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; RECOMBINANT PROTEINS; TREATMENT OUTCOME;

HUMAN ADENOVIRUS TYPE 2;

EID: 79952695303     PISSN: 10859195     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12013-010-9122-z     Document Type: Article

References (19)

1. Yu, J. Y. W.-b., & Li, B.-S. (2007). Precision radiotherapy of cancer. Shandong Science and Technology Press, 3, 392-721.
2. Cooper, J. S., Guo, M. D., Herskovic, A., Macdonald, J. S., Martenson, J. A., Jr., Al-Sarraf, M., et al. (1999). Chemoradiotherapy of locally advanced esophageal cancer: Long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA, 281, 1623-1627.
3. Koshy, M., Esiashvilli, N., Landry, J. C., Thomas, C. R., Jr., & Matthews, R. H. (2004). Multiple management modalities in esophageal cancer: Combined modality management approaches. Oncologist, 9, 147-159.
4. Swisher, S. G., Ajani, J. A., Komaki, R., Nesbitt, J. C., Correa, A. M., Cox, J. D., et al. (2003). Long-term outcome of phase II trial evaluating chemotherapy, chemoradiotherapy, and surgery for locoregionally advanced esophageal cancer. International Journal of Radiation Oncology, Biology, Physics, 57, 120-127.
5. Yin, W. (2006). Development of radiation treatment of esophageal cancer. Journal of Practical Oncology, 21, 99-103.
6. Cook, T., Wang, Z., Alber, S., Liu, K., Watkins, S. C., Vodovotz, Y., et al. (2004). Nitric oxide and ionizing radiation synergistically promote apoptosis and growth inhibition of cancer by activating p53. Cancer Research, 64, 8015-8021.
7. Kunisaki, R., Ikawa, S., Maeda, T., Nakazaki, Y., Kurita, R., Harata, M., et al. (2006). p51/p63, a novel p53 homologue, potentiates p53 activity and is a human cancer gene therapy candidate. The Journal of Gene Medicine, 8, 1121-1130.
8. Swisher, S. G., Roth, J. A., Komaki, R., Gu, J., Lee, J. J., Hicks, M., et al. (2003). Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clinical Cancer Research, 9, 93-101.
9. Anderson, S. C., Johnson, D. E., Harris, M. P., Engler, H., Hancock, W., Huang, W. M., et al. (1998). p53 gene therapy in a rat model of hepatocellular carcinoma: Intra-arterial delivery of a recombinant adenovirus. Clinical Cancer Research, 4, 1649-1659.
10. Hofseth, L. J., Hussain, S. P., & Harris, C. C. (2004). p53: 25 years after its discovery. Trends in Pharmacological Sciences, 25, 177-181.
11. Chen, C., Pan, J., & Xu, L. (2003). Recombinant adenovirus p53 agent injection combined with radiotherapy in treatment of nasopharyngeal carcinoma: A phase II clinical trial. Zhonghua Yi Xue Za Zhi, 83, 2033-2035.
12. Yunqing, Z., & Li, X. (2002). The significance of the expression of P53 and p21 in esophageal cancer and nasopharyngeal cancer. Henan Journal of Oncology, 15, 287-288.
13. Tsuda, H., Sata, M., Ijuuin, H., Kumabe, T., Uchida, M., Ogou, Y., et al. (2002). A novel strategy for remission induction and maintenance in cancer therapy. Oncology Reports, 9, 65-68.
14. Jain, P. T., & Gewirtz, D. A. (1999). Sustained enhancement of liposome-mediated gene delivery and gene expression in human breast tumour cells by ionizing radiation. International Journal of Radiation Biology, 75, 217-223.
15. Roth, J. A., Swisher, S. G., & Meyn, R. E. (1999). p53 tumor suppressor gene therapy for cancer. Oncology (Williston Park), 13, 148-154.
16. Shimada, H., Matsubara, H., & Ochiai, T. (2002). Gene therapy for esophageal cancer. Nippon Geka Gakkai Zasshi, 103, 371-375.
17. Shimada, H., Shimizu, T., Ochiai, T., Liu, T. L., Sashiyama, H., Nakamura, A., et al. (2001). Preclinical study of adenoviral p53 gene therapy for esophageal cancer. Surgery Today, 31, 597-604.
18. Shimada, H., Matsubara, H., Shiratori, T., Shimizu, T., Miyazaki, S., Okazumi, S., et al. (2006). Phase I/II adenoviral p53 gene therapy for chemoradiation resistant advanced esophageal squamous cell carcinoma. Cancer Science, 97, 554-561.
19. Lixin, Z., Limin, H., & Weizhen, Z. (2004). Synchronic radiotherapy-chemotherapy compared with radiotherapy alone in patients with upper and middle esophageal cancer. Tumor, 24, 303-304.